Methods paper proposes the Global Medical Device Risk Grammar for improving medical device classification across jurisdictions, suggesting future regulatory adaptability.
This record deposits a preprint methods paper introducing the Global Medical Device Risk Grammar (G-MDRG), a non-binding semantic-risk framework for medical-device classification interoperability. The paper addresses a recurring problem in global medical-device regulation: jurisdictional class labels, product codes, nomenclature systems, and classification rules can compress or obscure classification-relevant meaning. Such meaning may include intended use, clinical consequence, exposure and invasiveness, software autonomy, AI/adaptivity, cybersecurity dependency, evidence adequacy, lifecycle volatility, and vulnerable-population context. G-MDRG is proposed as an interpretive and documentation-oriented layer, not as a legal classifier, conformity-assessment pathway, regulatory approval tool, clinical decision system, or substitute for jurisdiction-specific expert, legal, regulatory-authority, FDA, notified-body, or competent-authority review. The framework separates baseline control intensity, lifecycle-governance concerns, and evidence-gap signalling through the Global Control Band (GCB), Lifecycle Governance Modifier (LGM), and Evidence Gap Modifier (EGM). It also introduces semantic-loss flags to identify cases where local classifications or product codes may not preserve risk-relevant meaning. A practical use of G-MDRG is early regional classification intelligence. For a given device, the framework can help identify which attributes are likely to drive classification concern across FDA, EU MDR, Swiss/EU-aligned, and SaMD/AI contexts. The resulting GCB, LGM, EGM, and semantic-loss outputs can support classification-rationale preparation, region-specific uncertainty mapping, evidence-gap identification, and prioritization of cases requiring expert, legal, or notified-body review. This is classification support and briefing, not binding classification determination. The manuscript includes feasibility-stage proxy evidence and an internal dry-run workflow. These analyses are intended to evaluate operational feasibility, rule stability, triage behaviour, semantic-loss detection, and expert-panel preparation. They do not constitute external expert validation, legal classification validation, regulatory validation, or evidence of global regulatory acceptance. Accordingly, the paper frames G-MDRG as a pre-normative regulatory-science contribution requiring future blinded expert adjudication, benchmark-corpus testing, usability evaluation, cross-jurisdictional validation, and governed codebook refinement before any stronger claims of validity, regulatory utility, or implementation readiness can be made.
No takes yet. Share an insight, caveat, or question.
Mehdi Zadehnour (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: